Little Dermira’s shares zoom up on promising PhIIb atopic dermatitis data — but the road ahead is ultra risky and flanked by heavily armed giants

Just over 18 months since Dermira agreed to pay Roche some $135 million in near-term cash for its disappointing IL-13 anti-inflammatory drug lebrikizumab, hustling it straight into a $200 million mid-stage study for atopic dermatitis, the biotech claims to have the efficacy data to back up its claims that they have a blockbuster on their hands.

Now they’re running it into a pivotal program, long after the drug floundered in asthma under the pharma giant.

Little Dermira is taking on the 600-pound gorilla in atopic dermatitis: the IL-13/IL-4 drug Dupixent, from Regeneron and Sanofi. And it won’t be easy.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,800+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->